BIOLOGICAL PREPARATIONS LIMITED

Financial Health Score: B+ (Provisional)

Explanation: This score is based on the structural and compliance data available. The patient exhibits an excellent regulatory heartbeat and a mature governance structure. However, without the quantitative "blood work" (profit & loss, balance sheet figures), a definitive numerical grade cannot be issued. The structural indicators suggest a stable, well-managed subsidiary, but the underlying financial vitals require full disclosure to confirm overall wellness.

1. Key Vital Signs

• Compliance Heartbeat: Strong & Steady The company’s regulatory heartbeat is robust. Accounts are filed up to December 2025 with no overdue flags, and confirmation statements are current. This indicates a disciplined administrative function with no symptoms of regulatory distress or administrative apathy.
• Corporate Governance Blood Pressure: Healthy With six directors, including specialized roles such as a Chief Financial And Operations Officer (Nicholas Rafael Davenport) and a scientific lead (Dr. Julia Maria Walsh), the leadership structure is well-defined. This suggests the company has the appropriate "organs" in place to manage both the commercial and scientific demands of a biotechnology firm.
• Ownership & Control (Genetic Makeup): Subsidiary Dependency The PSC register reveals that Biological Preparations Group Limited holds over 75% of the shares and voting rights, alongside the right to appoint and remove directors. This company is a wholly-owned subsidiary. Its financial health is inextricably linked to the "parent" organism; it relies on the Group for capital direction and strategic decision-making.
• Capital Reserves: Thin The allotted share capital sits at a mere £5,000. For a biotechnology research firm that has been operational since 2008, this is a very low equity base. It suggests the company is fueled by retained earnings or inter-company loans from its parent rather than a substantial share capital cushion.

2. Diagnosis

Based on the available structural data, Biological Preparations Limited presents as a mature, compliant, and operationally structured subsidiary with no visible signs of administrative distress.

The company has been "alive" for over 16 years, which is a positive indicator of business survivability, particularly in the capital-intensive biotechnology sector. The presence of a CFO/COO and a dedicated scientific director (Dr. Walsh) indicates that the company is actively pursuing its research and commercial objectives with the appropriate expertise.

However, the low share capital (£5,000) serves as a mild symptom of reliance on external or inter-group funding. Because the company is effectively controlled by the Group parent, it does not need a large share capital to assure external creditors, as the Group can act as a guarantor. The absence of actual financial figures (turnover, net assets, cash position) means we are evaluating the patient's outward appearance and medical records, but we haven't seen the blood test results—we know the company is functioning, but we cannot measure its profitability or liquidity.

3. Recommendations

To achieve a complete bill of health and move to a confirmed "A" grade, the following actions are recommended:

1. Conduct a Full Financial Blood Panel: Retrieve and analyze the full filed accounts (Profit & Loss, Balance Sheet, and Cash Flow statement) to assess liquidity ratios, debtor days, and operating margins. This is essential to ensure the company isn't surviving on life support via Group loans.
2. Review Inter-Company Liabilities: Given the subsidiary status and low share capital, it is critical to examine the nature of the company's debts. If the company is heavily reliant on parent company loans, the terms of these loans should be reviewed to ensure they aren't creating unsustainable financial pressure.
3. Monitor Working Capital Pulse: Biotech firms often experience long cash conversion cycles due to R&D timelines. Ensure that cash flow management remains a priority for the CFO/COO to prevent short-term liquidity cramps.